<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991766</url>
  </required_header>
  <id_info>
    <org_study_id>18205</org_study_id>
    <secondary_id>J2J-MC-JZLE</secondary_id>
    <nct_id>NCT04991766</nct_id>
  </id_info>
  <brief_title>A Study of [¹⁴C]-LY3484356 in Healthy Female Participants</brief_title>
  <official_title>An Open-label, Two-part Study of the Disposition and Absolute Bioavailability of [¹⁴C]-LY3484356 in Healthy Females of Non-Childbearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to measure how much of the study drug gets into the&#xD;
      bloodstream and how long it takes the body to get rid of it. This study has two parts. It&#xD;
      will involve a single dose of 14C radiolabeled LY3484356. This means that a radioactive&#xD;
      substance C14 will be incorporated into the study drug, to investigate the study drug and its&#xD;
      breakdown products, to find out how much of these pass from blood into urine, feces and&#xD;
      expired air. The study will last about 4 weeks. Screening is required within 28 days prior to&#xD;
      the start of the study and follow up is required approximately 7 days after discharge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">February 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal Excretion of LY3484356 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose up to Day 12 post dose</time_frame>
    <description>Fecal Excretion of LY3484356 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Excretion of LY3484356 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose up to Day 12 post dose</time_frame>
    <description>Urinary Excretion of LY3484356 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Absolute Bioavailability of LY3484356</measure>
    <time_frame>Predose up to Day 9 post dose</time_frame>
    <description>PK: Absolute Bioavailability of LY3484356</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC (0-∞)) of Total Radioactivity, LY3484356 and [¹⁴C]-LY3484356</measure>
    <time_frame>Predose up to Day 12 post dose</time_frame>
    <description>PK: (AUC (0-∞)) of Total Radioactivity, LY3484356 and [¹⁴C]-LY3484356</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of Total Radioactivity, LY3484356 and [¹⁴C]-LY3484356</measure>
    <time_frame>Predose up to Day 12 post dose</time_frame>
    <description>PK: Cmax of Total Radioactivity, LY3484356 and [¹⁴C]-LY3484356</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable).</measure>
    <time_frame>Predose up to Day 12 post dose</time_frame>
    <description>Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Metabolites of LY3484356</measure>
    <time_frame>Predose up to Day 12 post dose</time_frame>
    <description>Total Number of Metabolites of LY3484356</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[¹⁴C]-LY3484356 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of [¹⁴C]-LY3484356 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3484356 + [¹⁴C]-LY3484356 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3484356 administered orally followed by Single dose of [¹⁴C]-LY3484356 administered intravenously (IV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[¹⁴C]-LY3484356</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>[¹⁴C]-LY3484356 (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3484356</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3484356 + [¹⁴C]-LY3484356 (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[¹⁴C]-LY3484356 (IV)</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3484356 + [¹⁴C]-LY3484356 (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female participants of nonchildbearing potential. This includes females who are not&#xD;
             pregnant, non-lactating and either: Infertile due to surgical sterilization or&#xD;
             alternate medical cause/congenital or postmenopausal.&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 18.0 to 35.0 kilograms per meter squared&#xD;
             (kg/m²)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorders&#xD;
&#xD;
          -  Have evidence of human immunodeficiency virus (HIV) infection and/or positive human&#xD;
             HIV antibodies&#xD;
&#xD;
          -  Have known allergies to LY3484356, related compounds or any components of the&#xD;
             formulation as appropriate, or history of significant atopy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LabCorp CRU, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>608-443-1519</phone>
    </contact>
    <investigator>
      <last_name>Irene R Mirkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 1, 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism</keyword>
  <keyword>Absolute Bioavailability</keyword>
  <keyword>Disposition</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

